论文部分内容阅读
肺癌是世界范围内最常见和最致命的恶性肿瘤之一。非小细胞肺癌(non-small cell lung cancer,NSCLC)约占肺癌的80.0%~85.0%~([1])。由于早期症状不明显,多数患者确诊时多为中晚期,传统的治疗方法如手术、放疗、化疗能改善患者的近期疗效,但对生存期的延长作用有限。近年来,肺癌的靶向药物研究取得很大进展,其中抗表皮生长因子受体(EGFR)和棘皮动物微管相关类蛋白4与间变性淋巴激酶融合基因(EML4-ALK)的制剂已进入临床,并取得较好的治
Lung cancer is one of the most common and deadly malignancies in the world. Non-small cell lung cancer (NSCLC) accounts for about 80.0% ~ 85.0% of lung cancer ([1]). As the early symptoms are not obvious, the majority of patients diagnosed mostly in the late stage, the traditional treatment methods such as surgery, radiotherapy, chemotherapy can improve the short-term efficacy of patients, but the extension of the limited role of survival. In recent years, great progresses have been made in the research of targeted drugs for lung cancer, in which preparation of anti-epidermal growth factor receptor (EGFR) and echinoderm-associated protein 4 and anaplastic lymphokinase fusion gene (EML4-ALK) , And get better governance